Forte Biosciences マネジメント
マネジメント 基準チェック /14
Forte Biosciences' CEO is Paul A. Wagner, appointed in Jan 2018, has a tenure of 6.83 years. total yearly compensation is $1.45M, comprised of 42.7% salary and 57.3% bonuses, including company stock and options. directly owns 5.31% of the company’s shares, worth $323.82K. The average tenure of the management team and the board of directors is 3 years and 2.3 years respectively.
主要情報
Paul A. Wagner
最高経営責任者
US$1.5m
報酬総額
CEO給与比率 | 42.7% |
CEO在任期間 | 6.8yrs |
CEOの所有権 | 5.3% |
経営陣の平均在職期間 | 3yrs |
取締役会の平均在任期間 | 2.3yrs |
経営陣の近況
Recent updates
We're A Little Worried About Forte Biosciences' (NASDAQ:FBRX) Cash Burn Rate
Jul 17Is Forte Biosciences (NASDAQ:FBRX) In A Good Position To Deliver On Growth Plans?
Mar 14Large Forte Biosciences shareholder scolds company board of directors
Aug 24We're Hopeful That Forte Biosciences (NASDAQ:FBRX) Will Use Its Cash Wisely
Aug 17Forte Biosciences: Lots Of Clinical Risk Ahead And A Questionable Business Plan
Aug 16Forte Biosciences large shareholders make demands for company's future
Jul 07We Think Forte Biosciences (NASDAQ:FBRX) Needs To Drive Business Growth Carefully
Dec 23Forte Biosciences files for $300M mixed shelf offering
May 28Are Insiders Buying Forte Biosciences, Inc. (NASDAQ:FBRX) Stock?
Mar 13Do Institutions Own Forte Biosciences, Inc. (NASDAQ:FBRX) Shares?
Jan 19Forte Biosciences: FB-401 Potentially Best-In-Class In Atopic Dermatitis
Dec 18Who Has Been Buying Forte Biosciences, Inc. (NASDAQ:FBRX) Shares?
Nov 25Forte Biosciences readies equity offering
Oct 28CEO報酬分析
日付 | 総報酬 | 給与 | 会社業績 |
---|---|---|---|
Jun 30 2024 | n/a | n/a | -US$36m |
Mar 31 2024 | n/a | n/a | -US$32m |
Dec 31 2023 | US$1m | US$620k | -US$31m |
Sep 30 2023 | n/a | n/a | -US$30m |
Jun 30 2023 | n/a | n/a | -US$24m |
Mar 31 2023 | n/a | n/a | -US$18m |
Dec 31 2022 | US$1m | US$590k | -US$14m |
Sep 30 2022 | n/a | n/a | -US$12m |
Jun 30 2022 | n/a | n/a | -US$17m |
Mar 31 2022 | n/a | n/a | -US$19m |
Dec 31 2021 | US$5m | US$590k | -US$22m |
Sep 30 2021 | n/a | n/a | -US$23m |
Jun 30 2021 | n/a | n/a | -US$20m |
Mar 31 2021 | n/a | n/a | -US$49m |
Dec 31 2020 | US$777k | US$453k | -US$46m |
Sep 30 2020 | n/a | n/a | -US$43m |
Jun 30 2020 | n/a | n/a | -US$39m |
Mar 31 2020 | n/a | n/a | -US$5m |
Dec 31 2019 | US$525k | US$350k | -US$4m |
報酬と市場: Paul A.'s total compensation ($USD1.45M) is above average for companies of similar size in the US market ($USD655.65K).
報酬と収益: Paul A.'s compensation has increased whilst the company is unprofitable.
CEO(最高経営責任者
Paul A. Wagner (54 yo)
6.8yrs
在職期間
US$1,450,175
報酬
Dr. Paul A. Wagner, CFA, Ph.D. has been the Senior Vice President of Corporate Strategy & Development and Chief Business Officer at CANbridge Life Sciences Ltd. since October 16, 2017. Dr. Wagner leads CAN...
リーダーシップ・チーム
名称 | ポジション | 在職期間 | 報酬 | 所有権 |
---|---|---|---|---|
CEO, President & Chairman | 6.8yrs | US$1.45m | 5.31% $ 323.8k | |
Chief Financial Officer | 4.7yrs | US$722.98k | 0.57% $ 34.5k | |
Chief Medical Clinician & Director | less than a year | US$61.73k | 0% $ 0 | |
Chief Operating Officer | 2.5yrs | データなし | データなし | |
Chief Technical Officer | 3yrs | データなし | データなし |
3.0yrs
平均在職期間
62yo
平均年齢
経験豊富な経営陣: FBRX's management team is considered experienced (3 years average tenure).
取締役
名称 | ポジション | 在職期間 | 報酬 | 所有権 |
---|---|---|---|---|
CEO, President & Chairman | 7.8yrs | US$1.45m | 5.31% $ 323.8k | |
Chief Medical Clinician & Director | 2.7yrs | US$61.73k | 0% $ 0 | |
Independent Director | 1.8yrs | US$104.30k | 0.41% $ 24.8k | |
Independent Director | less than a year | データなし | データなし | |
Member of Scientific Advisory Board | no data | US$50.80k | データなし | |
Member of Scientific Advisory Board & Independent Director | 2.5yrs | US$62.73k | 0% $ 0 | |
Independent Director | 4.4yrs | US$97.73k | 0.27% $ 16.6k | |
Independent Director | less than a year | データなし | データなし | |
Independent Director | 2yrs | US$62.73k | 0% $ 0 | |
Member of Scientific Advisory Board | no data | データなし | データなし |
2.3yrs
平均在職期間
60yo
平均年齢
経験豊富なボード: FBRX's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.